全文获取类型
收费全文 | 1037篇 |
免费 | 80篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 51篇 |
妇产科学 | 22篇 |
基础医学 | 90篇 |
口腔科学 | 45篇 |
临床医学 | 93篇 |
内科学 | 255篇 |
皮肤病学 | 17篇 |
神经病学 | 41篇 |
特种医学 | 109篇 |
外科学 | 133篇 |
综合类 | 42篇 |
预防医学 | 77篇 |
眼科学 | 26篇 |
药学 | 71篇 |
中国医学 | 1篇 |
肿瘤学 | 57篇 |
出版年
2023年 | 7篇 |
2022年 | 8篇 |
2021年 | 8篇 |
2020年 | 9篇 |
2019年 | 8篇 |
2018年 | 26篇 |
2017年 | 14篇 |
2016年 | 21篇 |
2015年 | 20篇 |
2014年 | 9篇 |
2013年 | 27篇 |
2012年 | 53篇 |
2011年 | 63篇 |
2010年 | 34篇 |
2009年 | 47篇 |
2008年 | 32篇 |
2007年 | 57篇 |
2006年 | 38篇 |
2005年 | 35篇 |
2004年 | 31篇 |
2003年 | 43篇 |
2002年 | 34篇 |
2001年 | 24篇 |
2000年 | 24篇 |
1999年 | 21篇 |
1998年 | 23篇 |
1997年 | 41篇 |
1996年 | 35篇 |
1995年 | 21篇 |
1994年 | 22篇 |
1993年 | 24篇 |
1992年 | 8篇 |
1991年 | 35篇 |
1990年 | 22篇 |
1989年 | 19篇 |
1988年 | 22篇 |
1987年 | 17篇 |
1986年 | 16篇 |
1985年 | 23篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1982年 | 10篇 |
1981年 | 16篇 |
1980年 | 13篇 |
1979年 | 4篇 |
1978年 | 9篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1974年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有1137条查询结果,搜索用时 0 毫秒
11.
Massa O Iafusco D D'Amato E Gloyn AL Hattersley AT Pasquino B Tonini G Dammacco F Zanette G Meschi F Porzio O Bottazzo G Crinó A Lorini R Cerutti F Vanelli M Barbetti F;Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology Diabetology 《Human mutation》2005,25(1):22-27
Permanent neonatal diabetes mellitus (PNDM) is a rare condition characterized by severe hyperglycemia constantly requiring insulin treatment from its onset. Complete deficiency of glucokinase (GCK) can cause PNDM; however, the genetic etiology is unknown in most PNDM patients. Recently, heterozygous activating mutations of KCNJ11, encoding Kir6.2, the pore forming subunit of the ATP-dependent potassium (K(ATP)) channel of the pancreatic beta-cell, were found in patients with PNDM. Closure of the K(ATP) channel exerts a pivotal role in insulin secretion by modifying the resting membrane potential that leads to insulin exocytosis. We screened the KCNJ11 gene in 12 Italian patients with PNDM (onset within 3 months from birth) and in six patients with non-autoimmune, insulin-requiring diabetes diagnosed during the first year of life. Five different heterozygous mutations were identified: c.149G>C (p.R50P), c.175G>A (p.V59M), c.509A>G (p.K170R), c.510G>C (p.K170N), and c.601C>T (p.R201C) in eight patients with diabetes diagnosed between day 3 and 182. Mutations at Arg50 and Lys170 residues are novel. Four patients also presented with motor and/or developmental delay as previously reported. We conclude that KCNJ11 mutations are a common cause of PNDM either in isolation or associated with developmental delay. Permanent diabetes of non autoimmune origin can present up to 6 months from birth in individuals with KCNJ11 and EIF2AK3 mutations. Therefore, we suggest that the acronym PNDM be replaced with the more comprehensive permanent diabetes mellitus of infancy (PDMI), linking it to the gene product (e.g., GCK-PDMI, KCNJ11-PDMI) to avoid confusion between patients with early-onset, autoimmune type 1 diabetes. 相似文献
12.
13.
Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency 总被引:1,自引:0,他引:1
Hong YS; Kerr DS; Craigen WJ; Tan J; Pan Y; Lusk M; Patel MS 《Human molecular genetics》1996,5(12):1925-1930
An infant girl with elevated blood lactate, pyruvate, and plasma
branched-chain amino acids was diagnosed with dihydrolipoamide
dehydrogenase (E3; dihydrolipoamide: NAD+ oxidoreductase, EC 1.8.1.4)
deficiency. Activities of the pyruvate dehydrogenase complex and E3 from
patient were 26 and 2% of controls in blood lymphocytes, and 11 and 14% in
cultured skin fibroblasts, respectively. Western blot analysis demonstrated
that the amount of E3 protein in fibroblasts from the patient and her
father was about half of controls, while Northern blot analysis showed
normal amounts of E3 RNA. DNA sequencing of cloned full-length E3 cDNAs
from the patient revealed two mutations in separate alleles. One is a
single base insertion of an extra adenine in the last codon of the leader
peptide sequence (TAC-->TAAC) leading to a nonsense mutation which
results in the premature termination of the precursor E3 polypeptide
(Y35X). The other is a missense mutation due to substitution of guanine for
adenine, causing an Arg-->Gly substitution at amino acid 460 of the
mature protein (R460G) which triggers the loss of E3 activity probably by
structural change in the E3 dimer. DNA sequencing of E3 cDNAs from the
parents demonstrated that the nonsense mutation was inherited from the
father and the missense mutation was inherited from the mother.
相似文献
14.
15.
16.
Verweij J.; Wanders J.; Nielsen A. L.; Pavlidis N.; Calabresi F.; Huinink W. ten Bokkel; Bruntsch U.; Piccart M.; Franklin H.; Kaye S. B.; On behalf of the EORTC Early Clinical Trials Group 《Annals of oncology》1994,5(4):375-376
PURPOSE:: To test the antitumor activity of Elsamitrucin in metastaticcancer of the breast, colon and rectum, non-small cell lungand ovary. PATIENTS AND METHODS:: Eligibility required histologically proven cancer. Patientswith colorectal or non-small cell lung cancer could not havereceived prior chemotherapy. Patients were entered if WHO PSwas 2 and organ functions were normal. Treatment consisted ofElsamitrucin 25 mg/m2/week given as a 510 min infusionfor at least 36 weekly doses. RESULTS:: One hundred and five patients entered the studies, 97 were eligible,94 are evaluable for toxicity and 75 for response. Toxicitymainly consisted of mild nausea/vomiting, and less frequentlyreversible hepatotoxicity and malaise. No objective responseswere seen. CONCLUSION:: Elsamitrucin at this dose and schedule is not an active drugin metastatic breast cancer, colorectal cancer, non-small celllung cancer or ovarian cancer. Elsamitrucin, phase II, breast, colorectum, nonsmall cell lung, ovary 相似文献
17.
18.
19.
20.